Announcements Trials
Browse Landscape

Phase

Phase 3 2Phase 2 1

Status

Recruiting 2Active not recruiting 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3Observational 2Expanded_access 1

Sponsor

Cancer Type

Thoracic 3Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 3

Interventions

Carboplatin 1152Cisplatin 876Pemetrexed 834pembrolizumab 608Paclitaxel 598Docetaxel 535Gemcitabine 424Radiotherapy 377Erlotinib Hydrochloride 367Nivolumab 322Bevacizumab 322Etoposide 295durvalumab 254Drug Therapy 233osimertinib 218atezolizumab 208Radiosurgery 190Gefitinib 177Vinorelbine 145130-nm albumin-bound paclitaxel 124Magnetic Resonance Spectroscopy 121Ipilimumab 118Cetuximab 113anlotinib 104tislelizumab 103Topotecan 101Cyclophosphamide 101Taxes 99Irinotecan 95Albumin-Bound Paclitaxel 92

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Interventional × taletrectinib × Thoracic × Clear all
NCT07154706 2026-05-19

Phase 3 Study of Taletrectinib vs Placebo as an Adjuvant Therapy in ROS1 Positive NSCLC (TRUST-IV)

Nuvation Bio Inc.

Phase 3 Recruiting
180 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT06564324 2026-04-13

A Phase III Study Comparing Taletrectinib With Standard Therapy in ROS1 Positive Locally Advanced or Metastatic Non-small Cell Lung Cancer Patients

Nuvation Bio Inc.

Phase 3 Recruiting
194 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

NCT04919811 2026-01-07

TRUST-II

Nuvation Bio Inc.

Phase 2 Active not recruiting
217 enrolled 1 FDA
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡